Zinc invests in Anemo Labs

Deal terms as reported in the coverage below.

Decision brief

What changed

Zinc led Anemo Labs’ £700,000 pre-seed round, with participation from SFC Capital and support from Innovate UK. Anemo said it will use the funding to expand smell-data collection and sensor development and continue clinical validation of its AI-driven electronic nose for urine-based, non-invasive disease screening.

Why it matters

This is a funded step toward AI-enabled diagnostic sensing beyond imaging and text, specifically using volatile organic compounds from body emissions as a screening signal. For leaders in healthcare, diagnostics, or applied AI, the decision relevance is whether to monitor or partner around emerging multimodal sensing approaches that may create new data assets, clinical workflows, and device-software integration requirements if validation continues.

Affected roles

CEO CTO COO

Evidence

The coverage comes from a single Tech.eu report describing the £700,000 pre-seed raise, the named investors, and the intended use of funds. The same report also provides the product focus and an early technical result: 84.15% classification across 12 scent categories using the Sniffin' Sticks protocol.

What remains uncertain

The report does not establish clinical performance for disease detection, regulatory pathway, commercialization timing, or whether the early 84.15% result translates to real-world screening accuracy. It also does not specify patient cohort size, validation methodology, or the terms and duration of Innovate UK support, so any assessment of near-term adoption remains assumption-dependent.

Monitor next

Watch for published clinical-validation results for the urine-based screening use case, especially disease-specific sensitivity/specificity data and any regulatory or pilot deployment milestones.

Analytical support, not advice — assumptions and open questions stated above.

Source coverage